Search
Chlorophetanol
go.drugbank.com/drugs/DB11368ExperimentalChlorophetanol is an agent known to have antifungal activities.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseMavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized … Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist.
Categories: CXC Chemokine Receptor 4 AntagonistABX1100
go.drugbank.com/drugs/DB17655InvestigationalIt was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978] … ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.
Pumactant
go.drugbank.com/drugs/DB04955ExperimentalPumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates.
Ropidoxuridine
go.drugbank.com/drugs/DB06485InvestigationalRopidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Eritoran
go.drugbank.com/drugs/DB04933InvestigationalIt is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Categories: Toll-Like Receptor 4, antagonists & inhibitorsVT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Bizalimogene ralaplasmid
go.drugbank.com/drugs/DB16113InvestigationalAnal or Anal/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2). … Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related
Echinacoside
go.drugbank.com/drugs/DB15488Investigational[A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,